The US medical devices industry saw a drop of 2.8% in overall deal activity during March 2019, when compared with the last 12-month average, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
A total of 69 deals worth $778.29m were announced in March 2019, compared to the 12-month average of 71 deals.
Venture financing was the leading category in the month in terms of volume with 45 deals which accounted for 65.2% of all deals.
In second place was M&A with 20 deals, followed by private equity with four transactions, respectively accounting for 29% and 5.8% of overall deal activity in the country’s medical devices industry during the month.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn terms of value of deals, M&A was the leading deal category in the US medical devices industry with total deals worth $507.48m, while venture financing and private equity deals totalled $268.31m and $2.5m, respectively.
US medical devices industry deals in March 2019: Top deals
The top five medical devices industry deals accounted for 75.3% of the overall value during March 2019.
The combined value of the top five medical devices industry deals stood at $585.7m, against the overall value of $778.29m recorded for the month. The top announced US medical devices industry deal tracked by GlobalData in March 2019 was Alcon Laboratories’ $285m acquisition of PowerVision.
In second place was the $220m acquisition of MyoScience by Pacira Pharmaceuticals and in third place was Berwind Private Equity, Fisk Ventures, Life Sciences Greenhouse of Central Pennsylvania, Roche Venture Fund and Vivo Capital’s $38.7m venture financing of Maculogix.
The $22m venture financing of Ossio by OCV Partners, Ortho Vision and Secocha Ventures and Ben Franklin Technology Partners of Northeastern Pennsylvania, Life Sciences Greenhouse of Central Pennsylvania, Originate Ventures and Oscor’s venture financing of Micro Interventional Devices for $20m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.
